Mycobacterium ulcerans infection treated by Rifater®, pyrazynamide, Myambutol®, and surgery: A case report with a 6-year follow-up;Infection à Mycobacterium ulcerans traitée par Rifater®, pyrazynamide, Myambutol® associés à la chirurgie. À propos d'un cas avec un recul de six ans

Medecine et Maladies Infectieuses

Volumn 38, Issue 3, 2008, Pages 156-158

  Kibadi, K ^a,b,c  

^a UNIVERSITY OF KINSHASA   (Congo)

^b MINISTÈRE DE LA SANTÉ   (Congo)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Myambutol; Mycobacterium ulcerans; Pyrazynamide; Rifater

Indexed keywords

ETHAMBUTOL; PYRAZINAMIDE; RIFATER;

ARTICLE; BURULI ULCER; CASE REPORT; COMBINATION CHEMOTHERAPY; CONGO; FEMALE; FOLLOW UP; HUMAN; MYCOBACTERIOSIS; MYCOBACTERIUM ULCERANS; SCHOOL CHILD;

ANTI-BACTERIAL AGENTS; BURULI ULCER; CHILD; CHLORAMINES; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISONIAZID; MASTECTOMY; METRONIDAZOLE; MYCOBACTERIUM ULCERANS; NITROFURANTOIN; PLEURISY; PREDNISOLONE; PYRAZINAMIDE; RECURRENCE; RIFAMPIN; SKIN TRANSPLANTATION;

EID: 43049173607     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2007.09.009     Document Type: Article

References (10)

1. World Health Organization. Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer) (2004), Geneva: The Organization, WHO/CDS/CPE/GBUI/2004 p. 33
2. Kibadi K. Ulcère à Mycobacterium ulcerans : prise en charge chirurgicale dans 102 observations en République Démocratique du Congo. Med Trop 65 (2005) 444-448
3. Debacker M., Aguiar J., Steunou C., Zinsou C., Meyers W.M., and Portaels F. Buruli ulcer recurrence, Benin. Emerg Infect Dis 11 (2005) 584-589
4. Kibadi K. Les rechutes après traitement de l'ulcère de Buruli par la chirurgie en Afrique. Bull Soc Pathol Exot 99 (2006) 230-235
5. Kibadi K., Muyembe T., Phanzu D., Mbala L., Meyers W.M., and Portaels F. Association large ulcère de Buruli thoracoabdominal et pleurésie massive homolatérale : aspects diagnostiques et difficultés de prise en charge ; à propos d'un cas. Med d'Afrique Noire 51 (2004) 643-648
6. Etuaful S., Carbonnelle B., Grosset J., Lucas S., Horsfield C., Phillips R., et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 49 8 (2005) 3182-3186
7. Kibadi K., Tsakala T.M., Mputu-Yamba J.B., Muyembe T., Kashongwe M., and Imposo B. Essai thérapeutique de l'association chloramine-métronidazole-nitrofurandoïne dans le traitement local de l'ulcère de Buruli surinfecté. Med Afr Noire 49 (2002) 239-243
8. World Health Organization. In: Portaels F., Johnson P., and Meyers W.M. (Eds). Buruli ulcer : diagnosis of Mycobacterium ulcerans disease (2001), Geneva: The Organization, WHO/CDS/CPE/GBUI/2001.4 p. 92
9. Teelken M.A., Sienstra Y., Ellen D.E., Quarshie E., Van der Graaf W.T., and Van der Werf T.S. Buruli Ulcer: differences in treatment outcome between two centres in Ghana. Acta Trop 88 1 (2003) 51-56
10. Bretzel G., Siegmund V., Ralt P., Van Vloten F., Ngos F., Thompson W., et al. Post-surgical accessment of excised tissue from patients with Buruli ulcer disease: progression of infection in macroscopically healthy tissue. Trop Med Int Health 10 11 (2005) 1199-1206